Search Within

Brigitte Senechal

  1. "Sloan Kettering Institute Postdocs"
Formats
  1. Meeting Abstract (9)
  2. Journal Article (2)
Groups
  1. Center for Hematologic Malignancies (11)
  2. Department of Medicine (11)
  3. Hematologic Malignancies Research (11)
  4. Hematologic Malignancies, Division of (11)
  5. Sloan Kettering Institute Postdocs (11)
  6. Adult Leukemia (10)

More Groups

People
  1. Isabelle Riviere (10)
  2. Jae Park (10)
  3. Michel Sadelain (8)
  4. Xiuyan Wang (8)
  5. Devanjan Sikder (6)
  6. Maria Palomba (5)

More People

Years
  1. 2023 (2)
  2. 2022 (3)
  3. 2021 (3)
  4. 2020 (1)
  5. 2018 (2)
Publications
  1. Blood (5)
  2. Cytotherapy (2)
  3. Annals of Oncology (1)
  4. Cancer Discovery (1)
  5. Clinical Pharmacology & Therapeutics (1)
  6. New England Journal of Medicine (1)
Publishers
  1. American Society of Hematology (5)
  2. Elsevier Science Ltd. (2)
  3. American Association for Cancer Research (1)
  4. Massachusetts Medical Society (1)
  5. Nature Publishing Group (1)
  6. Oxford University Press (1)

Results (11)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase I study of CD19-targeted 19(T2)28z1xx CAR T cells in adult patients with relapsed or refractory diffuse large B-cell lymphoma
    Meeting Abstract

    Park, J. H.; Palomba, M. L.; Devlin, S. M.; Valtis, Y. K.; Sikder, D. S.; Senechal, B.; Wang, X.; Cathcart, E.; Liotta, K.; Yu, A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Characterizing the relationship between cellular kinetics and response to support dosing recommendations for Cd19-targeted 19(T2)28z1xx cell therapy
    Meeting Abstract

    Li, J.; Singh, R.; Dey, A.; Sellner, L.; Liu, R.; Dash, A.; Park, J.; Palomba, M.; Mansilla-Soto, J.; Senechal, B.; more...
    Clinical Pharmacology & Therapeutics (2023)

    Fulltext@MSK | Save
  • A phase I study of CD19-targeted 19(T2)28z1XX CAR T cells in adult patients with relapsed or refractory diffuse large B-cell lymphoma
    Meeting Abstract

    Park, J. H.; Palomba, M. L.; RivieĢ€re, I.; Sikder, D. S.; Senechal, B.; Wang, X.; Bermudez, V. P.; Cathcart, E. R.; Liotta, K.; Joseph, J.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • GPRC5D-targeted CAR T cells for myeloma
    Journal Article

    Mailankody, S.; Devlin, S. M.; Landa, J.; Nath, K.; Diamonte, C.; Carstens, E. J.; Russo, D.; Auclair, R.; Fitzgerald, L.; Cadzin, B.; more...
    New England Journal of Medicine (2022)

    Fulltext@MSK | Save
  • Discovery proteomics for analytes to predict cytokine release syndrome on day of infusion of chimeric antigen receptor (CAR) T cells
    Meeting Abstract

    Lakkaraja, M.; Hosszu, K.; Mcavoy, D.; Mauguen, A.; Purdon, T. J.; Auchincloss, T.; Klein, E.; Khakoo, Y.; Santomasso, B.; Senechal, B.; more...
    Cytotherapy (2022)

    Fulltext@MSK | Save
  • Phase I first-in-class trial of MCARH109, a G protein coupled receptor class C group 5 member D (GPRC5D) targeted CAR T cell therapy in patients with relapsed or refractory multiple myeloma
    Meeting Abstract

    Mailankody, S.; Diamonte, C.; Fitzgerald, L.; Kane, P.; Wang, X.; Sikder, D. S.; Senechal, B.; Bermudez, V. P.; Frias, D.; Morgan, J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Promoting functional persistence in solid tumor CAR T-cell therapy: Mesothelin-targeted CAR (M28z1XXPD1DNR) with T-cell intrinsic PD1 dominant negative receptor
    Meeting Abstract

    Adusumilli, P. S.; Amador, A. M.; Chintala, N.; Hou, Z.; Offin, M.; Pineda, J.; Senechal, B.; Quach, H. T.; Bellis, R.; Banerjee, S.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Predictors for neurotoxicity on day of infusion of chimeric antigen receptor (CAR) T cells using discovery proteomics platform
    Meeting Abstract

    Lakkaraja, M.; Hosszu, K.; McAvoy, D.; Mauguen, A.; Purdon, T. J.; Auchincloss, T.; Klein, E.; Khakoo, Y.; Santomasso, B.; Senechal, B.; more...
    Cytotherapy (2021)

    Fulltext@MSK | Save
  • A phase I study of CD19-targeted 19(T2)28z1xx CAR T cells in adult patients with relapsed or refractory B-cell malignancies
    Meeting Abstract

    Park, J. H.; Riviere, I.; Sikder, D. S.; Bermudez, V. P.; Senechal, B.; Wang, X.; Auchincloss, T. H.; Diamonte, C.; Halton, E.; Palomba, M. L.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Clinical responses and pharmacokinetics of MCARH171, a human-derived BCMA targeted CAR T cell therapy in relapsed/refractory multiple myeloma: Final results of a phase I clinical trial
    Meeting Abstract

    Mailankody, S.; Ghosh, A.; Staehr, M.; Purdon, T. J.; Roshal, M.; Halton, E.; Diamonte, C.; Pineda, J.; Anant, P.; Bernal, Y.; more...
    Blood (2018)

    Fulltext@MSK | Save